Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
出版年份 2022 全文链接
标题
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
作者
关键词
-
出版物
JOURNAL OF HEADACHE AND PAIN
Volume 23, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-03-19
DOI
10.1186/s10194-022-01408-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
- (2021) J. Talbot et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and Tolerability of Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
- (2021) Fred Cohen et al. PAIN MEDICINE
- Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
- (2021) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
- (2021) Marcello Silvestro et al. Frontiers in Neurology
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series
- (2021) Tahlia Toni et al. NEUROLOGICAL SCIENCES
- Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
- (2021) Raffaele Ornello et al. Frontiers in Neurology
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- European headache federation consensus on the definition of resistant and refractory migraine
- (2020) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group
- (2020) Simona Sacco et al. Expert Review of Neurotherapeutics
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
- (2020) Gregor Broessner et al. HEADACHE
- One year experience with erenumab: real-life data in 30 consecutive patients
- (2020) Angelo Ranieri et al. NEUROLOGICAL SCIENCES
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review
- (2019) Peer Tfelt-Hansen et al. CEPHALALGIA
- The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
- (2019) Jan Lewis Brandes et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- CGRP as the target of new migraine therapies — successful translation from bench to clinic
- (2018) Lars Edvinsson et al. Nature Reviews Neurology
- CGRP Antibodies as Prophylaxis in Migraine
- (2018) Lars Edvinsson CELL
- My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed
- (2018) Paolo Martelletti et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
- (2014) Modar Khalil et al. JOURNAL OF HEADACHE AND PAIN
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search